Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell save search
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
Published: 2023-03-14 (Crawled : 23:00) - biospace.com/
ABCL | $4.005 3.49% 3.37% 1.1M
|
|
| O: 3.1%
H: 1.83%
C: -1.05%
t-cell
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.64 3.53% 3.41% 24K
|
Health Technology
|
| O: -3.54%
H: 2.09%
C: -4.19%
talen research meeting breast association presentation cancer negative
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-03-09 (Crawled : 13:00) - prnewswire.com
SNGX | $0.408 -5.34% -5.64% 620K
|
Health Technology
|
| O: -2.09%
H: 14.23%
C: 8.9%
treatment fda drug meeting t-cell application
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
BCAB | $2.17 3.09% 3.0% 870K
|
|
| O: -0.63%
H: 2.22%
C: -8.25%
ba3182 treatment fda clearance drug t-cell application
TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
TCBP | $1.58 6.83% 6.39% 130K
|
|
| O: 2.55%
H: 0.0%
C: -34.29%
research aml publication
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
Published: 2023-02-16 (Crawled : 15:20) - globenewswire.com
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -1.48%
H: 0.55%
C: 0.08%
PDSB | $2.99 13.04% 11.54% 680K
|
Health Technology
|
| O: -0.11%
H: 2.74%
C: -1.37%
preclinical biotech publication
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
NEXI | $3.72 6.59% 6.18% 45K
|
|
| O: 78.05%
H: 11.51%
C: -17.79%
cibmtr response therapy
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
Published: 2023-02-15 (Crawled : 15:00) - biospace.com/
ENLV | News | $1.28 -3.03% -3.13% 51K
|
Health Technology
|
| O: -0.25%
H: 2.46%
C: 2.42%
patent t-cell
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-02-14 (Crawled : 13:00) - prnewswire.com
SNGX | $0.408 -5.34% -5.64% 620K
|
Health Technology
|
| O: -31.38%
H: 19.35%
C: 19.35%
treatment fda drug t-cell application
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Published: 2023-02-09 (Crawled : 19:00) - globenewswire.com
IMMX | $2.19 0.0% 190K
|
|
| O: -5.14%
H: 4.53%
C: -12.08%
nxc-201 biopharma expansion meeting t-cell trial response
Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Published: 2023-02-09 (Crawled : 15:20) - biospace.com/
IMMX | $2.19 0.0% 190K
|
|
| O: -5.14%
H: 4.53%
C: -12.08%
nxc-201 expansion meeting t-cell trial response
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
tecartus t-cell leukemia trial therapy
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
Published: 2023-02-08 (Crawled : 14:20) - biospace.com/
ATRA | $0.6943 5.04% 4.8% 860K
|
Health Technology
|
| O: 0.0%
H: 0.89%
C: -7.69%
europe immunotherapy transfer t-cell approved authorization
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
Published: 2023-02-08 (Crawled : 14:00) - biospace.com/
IMNM | $15.31 -1.1% -1.11% 1.3M
|
Health Technology
|
| O: 0.19%
H: 0.93%
C: -0.56%
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
XNCR | $18.19 -1.03% -1.04% 490K
|
Health Technology
|
| O: 0.19%
H: 4.49%
C: 0.16%
BCEL P | $0.077 0.0% 14K
|
Health Technology
|
| O: -1.8%
H: 6.1%
C: -9.76%
tumor antibody
Frazier Life Sciences Adds Highly Experienced T Cell Immunologist to Team
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
sciences life
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Published: 2023-01-26 (Crawled : 23:00) - biospace.com/
SANA | $7.96 4.6% 4.4% 2.1M
|
|
| O: 1.49%
H: 1.05%
C: -3.15%
sc291 fda clearance drug application therapy
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)
Published: 2023-01-26 (Crawled : 15:00) - biospace.com/
COYA | News | $7.96 -0.5% -0.5% 38K
|
|
| O: -3.77%
H: 3.69%
C: 0.22%
treatment disease preclinical animal alzheimer’s potential
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2023-01-26 (Crawled : 13:20) - biospace.com/
CTMX | $1.675 0.3% 0.3% 260K
|
Health Technology
|
| O: 4.58%
H: 6.57%
C: 1.46%
probody collaboration t-cell therapeutics milestone
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Published: 2023-01-25 (Crawled : 14:00) - allogene.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: -2.14%
H: 4.18%
C: 2.83%
lung research preclinical therapeutics potential cancer
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.